Navigation Links
Nobel Prize Winner Bruce Beutler joins Sound Pharmaceuticals
Date:11/28/2012

SEATTLE, Nov. 28, 2012 /PRNewswire/ -- Sound Pharmaceuticals, Inc. is honored to have Bruce A. Beutler, a recipient of the 2011 Nobel Prize in Physiology or Medicine for his discoveries involving the activation of innate immunity, join the company as a scientific advisor. Dr. Beutler is currently the Director of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical Center. In addition, he has identified and characterized COMT2, a genetic mutation that leads to human deafness. "He is an expert in the molecular pathways and biology that are at the heart of our science, and is a tremendous addition to our Scientific Advisory Board," said Jonathan Kil, MD, Chief Medical Officer.

SPI has developed an orally delivered small molecule (SPI-1005) that is currently in mid-stage or Ph-II clinical trials for the prevention and treatment of noise induced hearing loss and chemotherapy induced ototoxicity and tinnitus. SPI found that the enzyme glutathione peroxidase 1 (GPx1) is diminished in several critical cells and tissues in the cochlea of mammals immediately following noise exposure. SPI-1005 treatment increases the expression of GPx1 and is thought to allow these affected cells and tissues to repair themselves, thus restoring auditory function and preventing the irreversible loss of auditory hair cells and supporting cells.

SPI is also developing a locally delivered drug for regenerating cells within the inner ear of mammals as a means to restore auditory function to the severely hearing impaired or deaf. By inhibiting p27Kip1, a cyclin dependent kinase inhibitor or CKI, supporting cell and auditory hair cell regeneration is stimulated in adult mice and Guinea pigs that were previously exposed to intense noise or ototoxic drugs. This novel proliferative and regenerative ability is absent in adult mammals, resulting in permanent and often progressive sensorineural hearing loss. This novel CKI technology could be applied to other neurodegenerative diseases.

Sound Pharmaceuticals, Inc. is a privately held biopharmaceutical company with a focus on developing the first drugs for hearing loss and brain injury. For more information please contact Eric Lynch, PhD, President, 206-634-2559 or visit www.soundpharma.com.

 


'/>"/>
SOURCE Sound Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
2. Breast Cancer Survivor Awarded Top Prize In 2012 Oncology On Canvas(SM) Art Competition
3. Archbishop Desmond Tutu and the International Childrens Peace Prize Winners Launch Remember2015
4. Women Health Expert GC-Rise Launches Obstetrician-gynecologist Prize
5. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
6. West Virginia Rx Program Named a Mutual of America 2012 Community Partnership Award Winner
7. 2012 Facility of the Year Awards Program Names Mercks Vaccine Bulk Manufacturing Facility (VBF) Program of Projects as Overall Winner
8. Winner Medical Announces Mailing of Definitive Proxy Materials for Special Meeting of Shareholders
9. Goodwin Biotechnology is a Three-Category Winner in the 2012 CMO Leadership Awards
10. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
11. Elsevier and Australasian Research Management Society Announce Winners of the 2012 Scopus Young Researcher of the Year Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):